US Patent Issued to Novartis, The Trustees of the University of Pennsylvania, University of Pittsburgh-Of the Commonwealth System of Higher Education on Feb. 24 for "Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor" (Massachusetts, Pennsylvania Inventors)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,559,562, issued on Feb. 24, was assigned to Novartis AG (Basel, Switzerland), The Trustees of the University of Pennsylvania (Philadelphia) and University of Pittsburgh-Of the Commonwealth System of Higher Education (Pittsburgh).

"Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor" was invented by Jennifer Brogdon (Sudbury, Mass.), Laura Alexandra Johnson (Media, Pa.), Carl H. June (Merion Station, Pa.), Andreas Loew (Boston), Marcela Maus (Lexington, Mass.), John Scholler (Narberth, Pa.) and Hideho Okada (Pittsburgh).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides compositions and methods for treating disea...